Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | DRP-104 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DRP-104 | DRP 104|DRP104|Sirpiglenastat | Sirpiglenastat (DRP-104) is the prodrug form of glutamine antagonist, which potentially modulates immune response and inhibits tumor growth (J Immunother Cancer. 2019; 7(Suppl 1): 282, Abs nr: P497). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04471415 | Phase Ib/II | DRP-104 Atezolizumab + DRP-104 | First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. | Recruiting | USA | DEU | 0 |